Clinical Solutions


An integrated suite of proprietary technology, custom services, and nanomedicine expertise to empower our clients to create transformative medicines that significantly improve human well being. 

We Offer a Complete Solution

An integrated suite of products, services and expertise to support you through every stage.

Stage 1


Formulation Development




We can help develop and optimize your nanoparticle’s physicochemical properties and biological activity. Let us help you identify critical quality attributes and draft drug product specifications. Our team can also help develop custom analytical methods for your nanoparticle formulations and raw materials.

Stage 2


Process Development

(Blaze System)



The Blaze System is next used either at PNI or installed at your site to develop and establish the process parameters for preparing your nanoparticle formulations. This development work is performed at an intermediate scale, to conserve your valuable therapeutic agents. We can also assist with optimizing the downstream processing steps of your products, such as Tangential Flow Filtration (TFF) and Sterile Filtration.

Stage 3

Process Translation to GMP System

gmp system1-2

The Clinical Solutions team can configure a GMP NanoAssemblr® System to meet your requirements. Formulations are translated from the Blaze to the GMP System confirming equivalency with demonstration batches. We can also assist with preparing and testing batches to support GLP-Tox studies.

Stage 4

Technology Transfer to GMP Drug Product Facility


We can help you transfer equipment, materials and analytical methods to your GMP manufacturing site along with the required documentation. We can also assist with the Qualification of the GMP NanoAssemblr® System, provide on-site training and prepare product-specific GMP Master Batch Records.

Stage 5

CMC Support for GMP Manufacturing


PNI can support your Chemistry Manufacturing & Controls (CMC) needs by providing oversight for the manufacture and testing of your Engineering & GMP batches.

Talk to a Clinical Solutions Team Member

The Clinical Solutions Team is ready for your transformative drug candidates.

Contact Us

NanoAssemblrⓇ Systems: Path to the Clinic

nanoassemblr-systems---path-to-the-clinical_finalweb-06 copy

Quality Management System

Every customer and project is unique, requiring a tailored approach with an eye for quality and efficiency. We pride ourselves on our ability to bring our collective knowledge and expertise in Quality Management to all of our partners. PNI has developed a Quality Management System (QMS) that aligns with the requirements of 21 CFR Parts 210 and 211 such that PNI’s customers receive Scale-Up system components that are in full compliance for cGMP manufacturing.

Clinical Partners


  • "As an Evonik affiliate specialized in liposomal drug delivery systems, we are pleased to offer our clients access to the NanoAssemblr GMP System, which will aid in the translation of drug candidates to clinical testing and ideally to commercial use." 
    - Don Enns, Vice President of Evonik Vancouver Laboratories
  • "We are excited about this promising collaboration and hope that it will propel our work forward as the ncRNA Core Facility focuses on the non-coding RNA portions of the genome for [the] discovery of novel biomarkers and targets for therapeutics from human disease tissue and clinical trial specimens."
    - Frank Slack, Director of the Harvard Medical School Initiative for RNA Medicine (HIRM) at BIDMC
  • "Ajinomoto Bio-Pharma Services has audited the PNI facilities in Vancouver and has qualified PNI's NanoAssemblr® GMP System and its components. We are excited to work with PNI to offer their purpose-designed manufacturing technology and unique nanomedicine expertise to our clients for the manufacture of nanoparticle-based medicines" 
    - Kristin DeFife, Ph.D., Vice President and Head of US Operations of Ajinomoto Bio-Pharma Services

Get Started

To learn how Precision NanoSystems accelerates nanomedicine development from an idea to clinical applications, contact our Technical Sales Team.

Get in Touch

Resource Center

Publication - Abstract

July 01, 2020

Journal of Controlled Release

Delivery of Self-amplifying mRNA Vaccines by Cationic Lipid Nanoparticles: The Impact of Cationic Lipid Select...

G. Lou, G. Anderluzzi, S.T. Schmidt, S. Woods, S. Gallorini, M. Brazzoli, F. Giusti, I. F...

Read More 阅读更多

Publication - Abstract

May 08, 2020


Investigating the Impact of Delivery System Design on the Efficacy of Self-Amplifying RNA Vaccines

G. Anderluzzi, G. Lou, S. Gallorini, M. Brazzoli, R. Johnson, D.T. O'Hagan, B.C. Baudner a...

Read More 阅读更多

Publication - Abstract

April 02, 2020

Journal of Controlled Release

Design of a Novel Vaccine Nanotechnology-based Delivery System Comprising CpGODN-protein Conjugate Anchored to...

D. Chatzikleanthous, S.T. Schmidt, G. Buffi, I. Paciello, R. Cunliffe, F. Carboni, M.R. Ro...

Read More 阅读更多

Publication - Abstract

December 31, 2019


Investigating Prime-Pull Vaccination through a Combination of Parenteral Vaccination and Intranasal Boosting

C.B. Roces, M.T. Hussain, S.T. Schmidt, D. Christensen and Y. Perrie

Read More 阅读更多

Publication - Abstract

May 31, 2019


mRNA Vaccines Against H10N8 and H7N9 Influenza Viruses of Pandemic Potential Are Immunogenic and Well Tolerate...

R.A. Feldman, R. Fuhr, I. Smolenov, A. Ribeiro, L. Panther, M. Watson, J.J. Senn, M. Smith...

Read More 阅读更多

Publication - Summary

May 18, 2019

Annals of Hematology

Lipid Nanoparticle-mediated siRNA Delivery for Safe Targeting of Human CML In Vivo

N. Jyotsana, A. Sharma, A. Chaturvedi, M. Heuser et al.

Read More 阅读更多
Resource Center 资源中心